Abstract
Our objective was to describe the use of selective serotonin reuptake inhibitors (SSRIs) in the entire Danish population of children and adolescents from 1995 to 2011. Data on filled SSRIs were obtained for all children in Denmark aged 5–17 during 1995–2011. The amount and type of SSRIs filled were calculated as well as incidence rates and prevalence proportions. Furthermore, we looked at concurrent use of other psychotropic drug treatment duration. A total of 23,547 children aged 5–17 used SSRIs during the study period, most commonly sertraline followed by citalopram. Overall, the incidence rate increased from 0.57 per 1,000 person years in 1997 to 3.30 in 2010 and fell to 2.55 in 2011, while the prevalence proportion rose from 0.1 per 1,000 children at the end of 1995 to 3.3 at the end of 2011. However, these findings were driven entirely by an increase among adolescents (12–17 years), where the prevalence proportion rose from 0.11 and 0.36 to 4.64 and 8.52 per 1,000 boys and girls, respectively. A significant proportion of SSRI users used other psychotropic drugs concurrently, most notably antipsychotics (12–28 %) and psychostimulants (10–33 %). About 50 % of adolescents and 40 % of children discontinued treatment within 12 months of initiation. We found a marked increase in the use of SSRI drugs among adolescents in Denmark between 1995 and 2011. Whether this increase reflects a true increase in disorder occurrence, an increase in diagnostic intensity or more aggressive treatment remains uncertain.
Similar content being viewed by others
References
Gibbons RD, Brown CH, Hur K, Marcus SM, Bhaumik DK, Erkens JA et al (2007) Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 164:1356–1363
Vitiello B, Swedo S (2004) Antidepressant medications in children. N Engl J Med 350:1489–1491
The Danish Ministry of Health and Prevention. (Guide to medicamental treatment of children and adolescents with psychiatric disorders, VEJ no 10332); Cited 11 Dec 2012. Available from www.retsinformation.dk/
European Medicines Agency (EMA). European Medicines Agency finalizes review of antidepressants in children and adolescents. EMEA/CHMP/128918/2005; Cited 11 Dec 2012. Available from: www.ema.europa.eu
Summary of Product Characteristics.; Cited 11 Dec 2012. Available from: www.produktresume.dk
Danish Medicines Agency. (Drugs against depression for children and adolescents); Cited 11/12/2012. Available from: www.laegemiddelstyrelsen.dk
Frank L (2000) Epidemiology. When an entire country is a cohort. Science 287:2398–2399
Kildemoes HW, Sorensen HT, Hallas J (2011) The Danish national prescription registry. Scand J Public Health 39:38–41
Thygesen LC, Ersboll AK (2011) Danish population-based registers for public health and health-related welfare research: introduction to the supplement. Scand J Public Health 39:8–10
National Institute for Health Data and Disease Control. Medstat.dk; Cited 4 April 2013. Available from: www.medstat.dk/en
WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2013. 2012 Oslo
European Medicines Agency (EMA). ICH Topic E 11: Clinical Investigation of Medicinal Products in the Paediatric Population. Note for guidance on clinical investigation of medicinal products in the paediatric population (CPMP/ICH/2711/99). 2001
Nissen JB, Thomsen PH (2008) Clinicians’ views on clinical examination and treatment of children and adolescents with obsessive-compulsive disorder (OCD). A Danish national survey study. Nord J Psychiatry 62:309–314
Bhatia SK, Rezac AJ, Vitiello B, Sitorius MA, Buehler BA, Kratochvil CJ (2008) Antidepressant prescribing practices for the treatment of children and adolescents. J Child Adolesc Psychopharmacol 18:70–80
Katz LY, Kozyrskyj AL, Prior HJ, Enns MW, Cox BJ, Sareen J (2008) Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults. CMAJ 178:1005–1011
Pamer CA, Hammad TA, Wu YT, Kaplan S, Rochester G, Governale L et al (2010) Changes in US antidepressant and antipsychotic prescription patterns during a period of FDA actions. Pharmacoepidemiol Drug Saf 19:158–174
Valluri S, Zito JM, Safer DJ, Zuckerman IH, Mullins CD, Korelitz JJ (2010) Impact of the 2004 food and drug administration pediatric suicidality warning on antidepressant and psychotherapy treatment for new-onset depression. Med Care 48:947–954
Murray ML, de Vries CS, Wong IC (2004) A drug utilisation study of antidepressants in children and adolescents using the general practice research database. Arch Dis Child 89:1098–1102
Wijlaars LP, Nazareth I, Petersen I (2012) Trends in depression and antidepressant prescribing in children and adolescents: a cohort study in The Health Improvement Network (THIN). PLoS One 7:e33181
Zoega H, Baldursson G, Hrafnkelsson B, Almarsdottir AB, Valdimarsdottir U, Halldorsson M (2009) Psychotropic drug use among Icelandic children: a nationwide population-based study. J Child Adolesc Psychopharmacol 19:757–764
Saastamoinen LK, Wallin M, Lavikainen P, Airaksinen MS, Sourander A, Bell JS (2012) Treatment duration with selective serotonin reuptake inhibitors among children and adolescents in Finland: a nationwide register study. Eur J Clin Pharmacol 68:1109–1117
Steffenak AK, Wilde-Larsson B, Nordstrom G, Skurtveit S, Hartz I (2012) Increase in psychotropic drug use between 2006 and 2010 among adolescents in Norway: a nationwide prescription database study. Clin Epidemiol 4:225–231
Fegert JM, Kolch M, Zito JM, Glaeske G, Janhsen K (2006) Antidepressant use in children and adolescents in Germany. J Child Adolesc Psychopharmacol 16:197–206
Koelch M, Prestel A, Singer H, Keller F, Fegert JM, Schlack R et al (2009) Psychotropic medication in children and adolescents in Germany: prevalence, indications, and psychopathological patterns. J Child Adolesc Psychopharmacol 19:765–770
Sevilla-Dedieu C, Kovess-Masfety V (2008) Psychotropic medication use in children and adolescents: a study from France. J Child Adolesc Psychopharmacol 18:281–289
Merikangas KR, He JP, Rapoport J, Vitiello B, Olfson M (2013) Medication use in US youth with mental disorders. JAMA Pediatr 167:141–148
Vitiello B, Zuvekas SH, Norquist GS (2006) National estimates of antidepressant medication use among US children, 1997–2002. J Am Acad Child Adolesc Psychiatry 45:271–279
Zito JM, Tobi H, de Jong-van den Berg LT, Fegert JM, Safer DJ, Janhsen K et al (2006) Antidepressant prevalence for youths: a multi-national comparison. Pharmacoepidemiol Drug Saf 15:793–798
The Danish BupBase. (The Danish Database for Child and Adolescent Psychiatry 2005–2010 Annual Reports); Cited 5 March 2013. Available from: www.bupnet.dk
The Danish Health and Medicines Authority. (Development in Child and Adolescent Psychiatry Activity 2007–2010); Cited 12 March 2013. Available from: www.sst.dk
Lee E, Teschemaker AR, Johann-Liang R, Bazemore G, Yoon M, Shim KS et al (2012) Off-label prescribing patterns of antidepressants in children and adolescents. Pharmacoepidemiol Drug Saf 21:137–144
Pottegard A, Bjerregaard BK, Glintborg D, Kortegaard LS, Hallas J, Moreno SI (2013) The use of medication against attention deficit/hyperactivity disorder in Denmark: a drug use study from a patient perspective. Eur J Clin Pharmacol 69:589–598
Pottegard A, Bjerregaard BK, Glintborg D, Hallas J, Moreno SI (2012) The use of medication against attention deficit hyperactivity disorder in Denmark: a drug use study from a national perspective. Eur J Clin Pharmacol 68:1443–1450
Diaz-Caneja CM, Espliego A, Parellada M, Arango C, Moreno C (2012) Polypharmacy with antidepressants in children and adolescents. Int J Neuropsychopharmacol 1–20 [Epub ahead of print]
Comer JS, Olfson M, Mojtabai R (2010) National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996–2007. J Am Acad Child Adolesc Psychiatry 49:1001–1010
Dean AJ, McDermott BM, Marshall RT (2006) Psychotropic medication utilization in a child and adolescent mental health service. J Child Adolesc Psychopharmacol 16:273–285
McIntyre RS, Jerrell JM (2009) Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study. J Clin Psychiatry 70:240–246
Schirm E, Tobi H, Zito JM, de Jong-van den Berg LT (2001) Psychotropic medication in children: a study from the Netherlands. Pediatrics 108:E25
Geller B, Tillman R, Bolhofner K, Zimerman B (2010) Pharmacological and non-drug treatment of child bipolar I disorder during prospective eight-year follow-up. Bipolar Disord 12:164–171
Moreno C, Laje G, Blanco C, Jiang H, Schmidt AB, Olfson M (2007) National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry 64:1032–1039
Duffy FF, Narrow WE, Rae DS, West JC, Zarin DA, Rubio-Stipec M et al (2005) Concomitant pharmacotherapy among youths treated in routine psychiatric practice. J Child Adolesc Psychopharmacol 15:12–25
Hunkeler EM, Fireman B, Lee J, Diamond R, Hamilton J, He CX et al (2005) Trends in use of antidepressants, lithium, and anticonvulsants in Kaiser Permanente-insured youths, 1994–2003. J Child Adolesc Psychopharmacol 15:26–37
Daviss WB (2008) A review of co-morbid depression in pediatric ADHD: etiology, phenomenology, and treatment. J Child Adolesc Psychopharmacol 18:565–571
Esbjorn BH, Hoeyer M, Dyrborg J, Leth I, Kendall PC (2010) Prevalence and co-morbidity among anxiety disorders in a national cohort of psychiatrically referred children and adolescents. J Anxiety Disord 24:866–872
Kunwar A, Dewan M, Faraone SV (2007) Treating common psychiatric disorders associated with attention-deficit/hyperactivity disorder. Expert Opin Pharmacother 8:555–562
Masi G, Perugi G, Toni C, Millepiedi S, Mucci M, Bertini N et al (2006) Attention-deficit hyperactivity disorder: bipolar comorbidity in children and adolescents. Bipolar Disord 8:373–381
Fontanella CA, Bridge JA, Marcus SC, Campo JV (2011) Factors associated with antidepressant adherence for Medicaid-enrolled children and adolescents. Ann Pharmacother 45:898–909
Conflict of interest
JH has participated in research projects funded by Pfizer with grants paid to the institution where he was employed. He has personally received fees for consultation from the Danish Association of Pharmaceutical Manufacturers and from Lundbeck. PD is a paid consultant for Fertin Pharma, Denmark. AP and HZ report no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pottegård, A., Zoëga, H., Hallas, J. et al. Use of SSRIs among Danish children: a nationwide study. Eur Child Adolesc Psychiatry 23, 1211–1218 (2014). https://doi.org/10.1007/s00787-014-0523-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00787-014-0523-1